Wanbury Clears Korea FDA Inspection with Zero Observations

Wanbury's Patalganga site successfully completed a 3-day MFDS (Korea FDA) regulatory inspection with zero observations.
The inspection confirms the facility's cGMP compliance per international rules, as MFDS is part of the PIC scheme.
Both of Wanbury's USFDA-approved API manufacturing sites (Patalganga and Tanuku) maintain a track record of zero-observation approvals.
The company is strengthening infrastructure with a new API manufacturing block at its Andhra Pradesh site, currently under validation.